CheckMate-214, 2017 trial summary

A randomised clinical trial investigating the effect of nivolumab + ipilimumab versus sunitinib in intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma

Studied treatment	nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by Opdivo 3 mg/kg every 2 weeks
Control treatment	sunitinib 50 mg once daily for 4 weeks, followed by 2 weeks off before continuation of treatment

Patients	intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma
Group sizes	-9 / -9

Blindness	open-label	Inclusion period
Follow-up duration		Centers
Lost to FU		geographical localisation
Primary endpoint	ORR, PFS, OS	Design	Parallel groups

phase 3

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018;378:1277-1290 [PMID: 29562145] link to pdf add to Mendeley

Links

ClinicalTrial.gov record NCT02231749

Registering number	NCT02231749 (see trial on clinicaltrials.gov)
Code Name